Roche ends development of Seragon asset

Roche (SIX:ROG; OTCQX:RHHBY) said it has halted development of RG6046, a selective estrogen receptor degrader (SERD) that it obtained via its acquisition of Seragon Pharmaceuticals Inc. in 2014.

The pharma had studied RG6046 in a Phase II trial to treat ER-positive, HER2-negative metastatic breast cancer...